

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle, *et al.*

Serial No: 09/545,283

Filed: April 7, 2000

For: METHODS AND MATERIALS
RELATING TO NOVEL C-TYPE
LECTIN RECEPTOR-LIKE
POLYPEPTIDES AND
POLYNUCLEOTIDES

Examiner: Souaya, Jehanne E.

Group: 1634

HAND DELIVERY

RECEIVED
TECH CENTER 1500/2960
02 NOV -6 AM 10:51

TRANSMITTAL LETTER

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Examiner Souaya:

Enclosed are the following items for filing in the above-referenced U.S. Patent

Application:

1. Response Under 37 CFR 1.111 to Office Action Mailed October 22, 2002, Corrected (Marked-up) version of the Drawings, Clean version of the Drawings.

The Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 501169. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: November 05, 2002

By: Luisa Bigornia

Luisa Bigornia
Attorney for Applicants
Registration No.: 45,974
HYSEQ, INC.
670 Almanor Avenue
Sunnyvale, CA 94085
(408) 524-8100 Telephone
(408) 524-8145 Facsimile

#2018
CMB
CD
11/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle, *et al.*

Serial No: 09/545,283

Filed: April 7, 2000

For: METHODS AND MATERIALS
RELATING TO NOVEL C-TYPE
LECTIN RECEPTOR-LIKE
POLYPEPTIDES AND
POLYNUCLEOTIDES

Examiner: Jehanne E. Souaya

Group: 1634

HAND DELIVERY

RECEIVED
TECH CENTER 1800/2300
02 NOV - 6 AM 10:52

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND RESPONSE UNDER
37 CFR § 1.111 TO OFFICE ACTION MAILED OCTOBER 22, 2002

Dear Examiner Souaya:

This is in response to the Office Action mailed October 22, 2002. Please consider this paper under 35 U.S.C. § 1.132. It is believed that no fees are required. However, if any fees are required in order to maintain the pendency of the instant application, the Examiner is expressly authorized to charge such to our Deposit Account No. 50-1169.

In the Office Action, the Examiner allowed claims 10, 11 and 20:

10. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6
11. A composition comprising the polypeptide of claim 10 and a carrier.
20. A kit comprising the polypeptide of claim 10.

OK to enter
9.4.
12/6/2002